Stratos Wealth Advisors LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 41.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 5,851 shares of the company's stock after selling 4,216 shares during the period. Stratos Wealth Advisors LLC's holdings in Novo Nordisk A/S were worth $503,000 as of its most recent filing with the SEC.
Several other large investors also recently modified their holdings of NVO. Novare Capital Management LLC boosted its position in Novo Nordisk A/S by 3.2% in the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company's stock valued at $325,000 after buying an additional 85 shares in the last quarter. Rosenberg Matthew Hamilton lifted its stake in Novo Nordisk A/S by 2.5% in the third quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company's stock valued at $454,000 after buying an additional 94 shares during the period. Spinnaker Trust increased its stake in shares of Novo Nordisk A/S by 1.1% in the 3rd quarter. Spinnaker Trust now owns 9,615 shares of the company's stock valued at $1,145,000 after acquiring an additional 100 shares in the last quarter. Marco Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 1.5% during the 3rd quarter. Marco Investment Management LLC now owns 6,702 shares of the company's stock valued at $798,000 after acquiring an additional 100 shares during the period. Finally, Carr Financial Group Corp boosted its stake in Novo Nordisk A/S by 5.1% during the third quarter. Carr Financial Group Corp now owns 2,100 shares of the company's stock worth $250,000 after acquiring an additional 101 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.
A number of analysts recently commented on the company. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Sunday, December 29th. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reissued an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $145.25.
Check Out Our Latest Stock Report on NVO
Shares of NVO stock traded down $0.78 during trading on Friday, hitting $86.39. The company's stock had a trading volume of 8,697,874 shares, compared to its average volume of 9,598,048. The business has a fifty day moving average of $91.46 and a 200-day moving average of $111.51. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The company has a market cap of $387.66 billion, a PE ratio of 26.26, a P/E/G ratio of 0.96 and a beta of 0.45.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.86 earnings per share for the current year.
The firm also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S's payout ratio is presently 21.88%.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.